Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Nephrol Dial Transplant (2016) 31: 337–348
Press Release: ERA-EDTA recommendation on the use of tolvaptan in polycystic kidney disease
9 February 2016
Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, Aresté N, Alonso de la Torre R, Caskey F, Couchoud C, Finne P, Heaf J, Hoitsma A, de Meester J, Pascual J, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT; ERA-EDTA Registry; EuroCYST Consortium; WGIKD; ERA-EDTA Registry. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv15-iv25. PubMed
Petzold K, Gansevoort RT, Ong AC, Devuyst O, Rotar L, Eckardt KU, Köttgen A, Pirson Y, Remuzzi G, Sandford R, Tesar V, Ecder T, Chaveau D, Torra R, Budde K, Le Meur Y, Wüthrich RP, Serra AL. Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv26-iv32. PubMed
Emma F, Nesterova G, Langman C, Labbé A, Cherqui S, Goodyer P, Janssen MC, Greco M, Topaloglu R, Elenberg E, Dohil R, Trauner D, Antignac C, Cochat P, Kaskel F, Servais A, Wühl E, Niaudet P, Van't Hoff W, Gahl W, Levtchenko E. Nephropathic cystinosis: an international consensus document. Nephrol Dial Transplant. 2014 Sep;29(suppl 4):iv87-iv94. Review. PubMed
Ars E, Bernis C, Fraga G, Martínez V, Martins J, Ortiz A, Rodríguez-Pérez JC, Sans L, Torra R; on behalf of the Spanish Working Group on Inherited Kidney Disease. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014 Sep;29(suppl 4):iv95-iv105. Review. PubMed
Devuyst O, Knoers NV, Remuzzi G, Schaefer F; Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association. (2014). Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 383:1844-59 PubMed
Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Caskey F, Collart F, Finne P, Fogarty DG, Groothoff JW, Hoitsma A, Nogier MB, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT; on behalf of the ERA-EDTA Registry; EuroCYST Consortium; the WGIKD. (2014). Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int 2014 May 14. PMID: 24827775 [Epub ahead of print] PubMed
Devuyst O*, Antignac C*, Bindels RJ*, Chauveau D*, Emma F*, Gansevoort R*, Maxwell PH*, Ong AC*, Remuzzi G*, Ronco P*, Schaefer F. * (2012) The ERA-EDTA Working Group on inherited kidney disorders. Nephrol Dial Transplant 27: 67-9 (* Equivalent senior author) PubMed
N. Users | Country |
35 | UNITED KINGDOM |
34 | ITALY |
33 | SPAIN |
29 | BELGIUM |
27 | THE NETHERLANDS |
24 | FRANCE |
24 | GERMANY |
18 | SWITZERLAND |
15 | ROMANIA |
10 | POLAND |
9 | SWEDEN |
8 | TURKEY |
7 | CZECH REPUBLIC |
7 | DENMARK |
5 | AUSTRALIA |
5 | U.S.A. |
5 | EGYPT |
4 | MONTENEGRO |
4 | PORTUGAL |
4 | CYPRUS |
4 | ALBANIA |
3 | INDIA |
3 | GREECE |
3 | NORWAY |
2 | F.Y.R. OF MACEDONIA |
2 | IRAN |
2 | AUSTRIA |
2 | P.R. CHINA |
2 | IRELAND |
2 | AFGHANISTAN |
2 | TUNISIA |
2 | SOUTH KOREA |
2 | TAIWAN, R.O.C. |
2 | BRAZIL |
2 | MOROCCO |
2 | RUSSIA |
1 | JORDAN |
1 | KOSOVO* |
1 | SAUDI ARABIA |
1 | HUNGARY |
1 | ALGERIA |
1 | SRI LANKA |
1 | LUXEMBOURG |
1 | LEBANON |
1 | SINGAPORE |
1 | GEORGIA |
1 | NIGERIA |
1 | EAST TIMOR |
1 | EL SALVADOR |
1 | ECUADOR |
1 | U.A.E. |
1 | IRAQ |
1 | ARMENIA |
1 | LITHUANIA |